Results for "psoriasis"

...Indication: lupus erythematosus. Brodalumab: human antibody ► interleukin-17 receptor. Indication: psoriasis, psoriatic arthritis, asthma. Canakinumab: human antibody ► interleukin-1 beta receptor. Indication...

...will result in increased tapinarof exposure. (Jett JE et al. 2022). Field of application/use Plaque psoriasis: A multicenter, open-label, phase IIa study (NCT04042103) evaluating the efficacy of tapinarof in t...

...also known as "CARD-containing MAGUK protein 2 or Carma 2) is a protein-coding gene associated with psoriasis vulgaris, pustular psoriasis generalisata, as well as the autosomal dominant form of pityriasis rub...

...n be affected. On the other hand, pre-existing cutaneous inflammatory diseases (e.g. lichen planus, psoriasis, sarcoidosis) can be activated or reactivated. As the autoreactive T-cell clones underlying irAEs a...

PSORS12 Definition Psoriasis 12, also known as psoriasis susceptibility 12, is a genetic locus associated with psoriasis. There...

PSORS13 Definition PSORS13 (Psoriasis Susceptibility 13) is a genetic locus associated with psoriasis. PSOS13 is located on chromosome 6q...

...al. It typically appears as early as 1 year of age and clinically exhibits characteristics of both psoriasis and pityriasis rubra pilaris. Erythrodermic courses are not rare. In the classifications of pityria...

...ts in a strong anti-inflammatory effect. Indication Moderate and severe, therapy-resistant forms of psoriasis vulgaris, dimethyl fumarate also approved in multiple sclerosis. Limited indication Hematological d...

...ammatory skin diseases that are accompanied by pustule formation. For example, generalized pustular psoriasis (GPP/Zumbusch type) (Farooq M et al. 2013).Other IL36RN-associated diseases are classified as forms...

...or the IL-36 receptor antagonist, are more common in patients diagnosed with both AGEP and pustular psoriasis than in unaffected individuals (Sidoroff A et al. 2007; Meier-Schiesser B et al. 2019; Navarini AA...

...se III studies (AMAGINE-2 and AMAGINE-3) in more than 1,800 patients with moderate to severe plaque psoriasis showed that 36.7% of patients in the 210 mg brodalumab group, 18.5% in a group with the IL-12/-23 a...

...s if their response to previous disease-modifying, anti-rheumatic drug therapy has been inadequate. Psoriasis vulgaris (moderate to severe plaque-type psoriasis in adults who have not responded to other system...

...peutic is interesting; a large number of publications are available in this regard. General therapy Psoriasis, spondyloarthritis (Spa) with axial as well as peripheral arthritis, ankylosing spondylitis, psoria...

...M. Behçet, dermatomyositis, sarcoidosis, T-cell lymphomas, pemphigus vulgaris, bullous pemphigoid, psoriasis vulgaris, atopic eczema (most severe forms), lichen planus mucosae (topical application also possib...

...nd are all inherited in an autosomal dominant manner, leading to a loss of melanocytes in the skin. Psoriasis: The integrity of the epidermal melanin unit is also disrupted in psoriasis (Nickoloff BJ 2004). It...

...s or candida infections.Exfoliatio areagta linguae occurs more frequently in patients with pustular psoriasis(Psoriasis pustulosa - Dreyer LN et al. 2012). In this context, the detection of IL36RN gene mutatio...

...ogous study results in other inflammatory models, such as arthritis, inflammatory bowel disease and psoriasis, confirmed the hypothesis of dual utilization of the IL-12p40 subunit by interleukins 12 and 23.Int...

...antly influences inflammatory processes is IL-17, which plays a central role in the pathogenesis of psoriasis, psoriatic arthritis and rheumatoid arthritis. As antipsoriatic and/or antirheumatic drugs there ar...

...suppressive and anti-inflammatory effect and is used for the treatment of moderate to severe plaque psoriasis. Spectrum of action Ixekinumab binds with high affinity to interleukin-17A (IL-17A) and inhibits th...

...esepigenetic ageingTumor subtypesExamples: Dermatology / Immunology: In inflammatory diseases (e.g. psoriasis vs. atopic dermatitis) distinct genetic profiles can be identified Th1/Th17-dominated patterns(IFN...

...nclude:AdiponectinC1q/tumor necrosis factor-related protein (CTRP) General information Resistin and psoriasis:In rodents, resistin is mainly produced by the WAT, whereas in humans it is mainly secreted by immu...

...ammatory and selective immunosuppressive effects. Tildrakizumab is used for the treatment of plaque psoriasis. The effects are based on the binding and inactivation of the cytokine interleukin-23 (IL-23). Phar...

...ments on cytotoxic cells, especially NK cells. Indication For moderately severe and severe forms of psoriasis vulgaris that require systemic treatment ( off-label use, not permitted in Europe!). Pregnancy/nurs...

...esterase-4 inhibitor) developed by Celegene for the indications spondylitis, psoriatic arthritis or psoriasis arthropathica, and moderate to severe psoriasis vulgaris (S3 guideline). A small monocentric study...

...® (bimekizumab) was launched on the German market on September 15, 2021 for the treatment of plaque psoriasis . Two anti-IL-17A antibodies, ixekizumab and secukinumab, have already been approved for the treatm...